Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 81

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 81
---
 also involve the improper use of information obtained in the course of clinical trials, which could
result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct, and the
precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in
protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws,
standards or regulations. Such actions could have a significant impact on our business and results of operations, including the imposition
of significant fines or other sanctions.

47

A cybersecurity incident and other technological
disruptions could negatively affect our business and our relationships with customers.

We use technology in substantially
all aspects of our business operations. The widespread use of technology, including mobile devices, cloud computing, and the internet,
gives rise to cybersecurity risks, including security breach, espionage, system disruption, theft and inadvertent release of information.
Our business involves the storage and transmission of numerous classes of sensitive and/or confidential information and intellectual property,
including information relating to suppliers, private information about employees, and financial and strategic information about us and
our business partners. If we fail to effectively assess and identify cybersecurity risks associated with the use of technology in our
business operations, we may become increasingly vulnerable to such risks. Additionally, while we have implemented measures to prevent
security breaches and cyber incidents, our preventative measures and incident response efforts may not be entirely effective. The theft,
destruction, loss, misappropriation, or release of sensitive and/or confidential information or intellectual property, or interference
with our information technology systems or the technology systems of third parties on which we rely, could result in business disruption,
negative publicity, brand damage, violation of privacy laws, loss of customers, potential liability and competitive disadvantage.

Use of social media platforms presents
new risks.

We believe that our potential
patient population is active on social media. Social media practices in the pharmaceutical and biotechnology industries are evolving,
which creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social
media platforms to comment on the effectiveness of, or adverse experiences with, a product candidate, which could result in reporting
obligations. In addition, there is a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments
about us or our product candidates on any social networking website. In addition, our employees or third parties with whom we contract,
such as